Supine Magnetic Resonance Imaging in Breast-Conserving Surgery Planning: A Systematic Review of Margin and Re-excision Outcomes.

Clin Breast CancerAug 26, 2026 (epub)
Clinical ResearchRadiology (Diagnostic)General Surgery

Henrique Mora, Diogo Cruz, Diana Gonçalves et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review assessed the impact of supine magnetic resonance imaging (SMRI) on positive surgical margin and re-excision rates in breast-conserving surgery (BCS). Analyzing 13 studies involving 1718 patients, the review found that SMRI was associated with a significantly lower risk of positive margins (relative risk 0.57) compared to conventional imaging, although evidence remains limited and preliminary.

Key findings

  • Positive margin rates with SMRI ranged from 0% to 25.9%.
  • SMRI was associated with a significantly lower risk of a positive margin (RR 0.57).
  • There was a nonsignificant reduction in re-excision rates (RR 0.64).

Why it matters

Achieving negative margins in breast-conserving surgery is crucial to minimize the need for re-excision. This review suggests that SMRI may enhance surgical planning and outcomes, potentially improving patient care.

What to keep in mind

The evidence base is limited, with only one randomized trial and most studies at serious risk of bias.

Source

PubMed · PMID 42759485

Published in Clin Breast Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.